Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Operating Income (2019 - 2026)

Pliant Therapeutics has reported Operating Income over the past 8 years, most recently at -$21.8 million for Q1 2026.

  • Quarterly Operating Income rose 63.06% to -$21.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$119.2 million through Mar 2026, up 49.25% year-over-year, with the annual reading at -$156.4 million for FY2025, 31.52% up from the prior year.
  • Operating Income was -$21.8 million for Q1 2026 at Pliant Therapeutics, up from -$23.6 million in the prior quarter.
  • Over five years, Operating Income peaked at -$21.8 million in Q1 2026 and troughed at -$62.0 million in Q3 2024.
  • The 5-year median for Operating Income is -$45.6 million (2025), against an average of -$42.2 million.
  • Year-over-year, Operating Income plummeted 59.67% in 2023 and then skyrocketed 63.06% in 2026.
  • A 5-year view of Operating Income shows it stood at -$37.4 million in 2022, then decreased by 25.77% to -$47.0 million in 2023, then dropped by 13.36% to -$53.3 million in 2024, then soared by 55.78% to -$23.6 million in 2025, then increased by 7.66% to -$21.8 million in 2026.
  • Per Business Quant, the three most recent readings for PLRX's Operating Income are -$21.8 million (Q1 2026), -$23.6 million (Q4 2025), and -$28.3 million (Q3 2025).